Pransky Seth M, Albright James T, Magit Anthony E
Children's Hospital and Health Center, San Diego, CA 92123, USA.
Laryngoscope. 2003 Sep;113(9):1583-7. doi: 10.1097/00005537-200309000-00032.
Cidofovir is an acyclic nucleotide phosphonate antiviral medication that has been used intralesionally for the treatment of severe respiratory papillomatosis (RRP) in pediatric patients. The long-term efficacy of this medication was assessed in 11 children with severe RRP who previously required operative debulking every 2 to 6 weeks to maintain airway patency.
Clinical case series.
Ten of these children have completed therapy. Five are disease free over a mean follow-up period of 51.6 months. Five other patients with active RRP decreased their mean severity scores from 17.8 (range 11-26) to 4.0 (range 2-6) and no longer require cidofovir. One patient continues to receive cidofovir for recurrent disease after an initial favorable response. Throughout the 6-year observational period, no patients demonstrated any adverse effects, laboratory abnormalities, or evidence of carcinogenesis.
Intralesional cidofovir is a useful adjunct for managing children with tenuous airways caused by previously uncontrolled papilloma.
西多福韦是一种无环核苷酸膦酸盐抗病毒药物，已被用于局部治疗儿科患者的重度呼吸道乳头状瘤病（RRP）。对11例重度RRP患儿评估了该药物的长期疗效，这些患儿此前每2至6周需要进行手术减瘤以维持气道通畅。
临床病例系列。
其中10名儿童已完成治疗。5名儿童在平均51.6个月的随访期内无疾病复发。另外5名患有活动性RRP的患者将其平均严重程度评分从17.8（范围11 - 26）降至4.0（范围2 - 6），不再需要西多福韦治疗。1名患者在最初有良好反应后因疾病复发继续接受西多福韦治疗。在整个6年的观察期内，没有患者出现任何不良反应、实验室异常或致癌证据。
病灶内注射西多福韦是治疗因先前未得到控制的乳头状瘤导致气道脆弱的儿童的一种有用辅助方法。
Zotero 插件